#### 1 Modeling infections and deaths averted due to COVID-19 vaccination strategies in Ghana

2

3 Sylvia K. Ofori,<sup>1</sup> Jessica S. Schwind,<sup>2</sup> Kelly L. Sullivan,<sup>1</sup> Gerardo Chowell, <sup>3</sup> Benjamin J.
4 Cowling,<sup>4</sup> Isaac Chun-Hai Fung<sup>1\*</sup>

5

# 6 Affiliations:

- 7 1 Department of Biostatistics, Epidemiology and Environmental Health Sciences, Jiann-
- 8 Ping Hsu College of Public Health, Georgia Southern University.
- 9 2 Institute for Health Logistics and Analytics, Georgia Southern University.
- 10 3 Department of Population Health Sciences, School of Public Health, Georgia State University.
- 11 4 WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of
- 12 Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong.
- 13
- 14 \*Correspondence should be addressed to Isaac Chun-Hai Fung, Ph.D., P.O. Box 7989,
- 15 Department of Biostatistics, Epidemiology and Environmental Health Sciences, Jiann-Ping Hsu
- 16 College of Public Health, Georgia Southern University, Statesboro, GA 30458-7989, USA.
- 17 Email: cfung@georgiasouthern.edu. Tel: +1 912 4785079.
- 18 Current affiliation of Dr. Sylvia K. Ofori is the Center for Communicable Disease Dynamics,
- 19 Department of Epidemiology, Harvard T. H. Chan School of Public Health.

# 20 Keywords: Africa, Western; COVID-19; Epidemiology; Epidemiological Models;

- 21 Vaccination.
- 22 Manuscript type: Research
- 23 Number of tables: 5
- 24 Number of figures: 2
- 25 Technical appendices attached: 2
- 26 **Running head:** Modeling COVID-19 vaccination strategies in Ghana

One-sentence summary: An age-stratified model of COVID-19 vaccination in Ghana found vaccinating individuals <65 years was associated with the lowest cumulative infections when one million persons were vaccinated over three months while prioritizing the elderly (65+) was associated with the lowest cumulative deaths.

## 31 Abstract (146, max=150 words)

32 This study assessed the impact of various COVID-19 vaccination strategies on health outcomes in 33 Ghana using an age-stratified compartmental model. The population was stratified into three age 34 groups: <25 years, 25-64 years, and 65+ years. Five vaccination optimization scenarios were explored, assuming that one million persons could be vaccinated in three versus six months. We 35 36 also performed uncertainty analysis by assuming that the available doses were halved and doubled. 37 The vaccine optimization strategies were assessed for the initial strain, followed by a sensitivity analysis for the delta variant by varying the reproduction number and vaccine efficacy. The results 38 39 showed that vaccinating individuals <65 years was associated with the lowest cumulative 40 infections when one million persons were vaccinated over three months for both the initial strain 41 and the delta variant. On the contrary, prioritizing the elderly (65+) was associated with the lowest 42 cumulative deaths for both strains.

#### 43 Main text (3412, max words=3500)

## 44 Introduction

Since the first case of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory 45 syndrome coronavirus 2 (SARS-CoV-2), was reported in China (1), the pandemic has spread to 46 47 Africa (2). Ghana reported its first case on March 12, 2020, with 161,157 cases and 1,445 deaths recorded as of April 21, 2022 (3, 4). The country introduced various public health measures when 48 49 the pandemic first hit the country, including school closures, travel bans, mask mandates, and 50 vaccination, which were associated with a decline in transmission (5). Ghana was the first country 51 to receive 600,000 doses of the Oxford-AstraZeneca COVID-19 vaccine AZD1222 (brand name: 52 Vaxzevria) vaccine on February 24, 2021, through the COVAX program (6). The vaccination 53 program was deployed in March 2021, with politicians and civil society leaders publicly taking 54 shots to boost the trust in the vaccine program (7). The first batch of the vaccines was targeted at the regions with the highest burden of COVID-19, namely, the Greater Accra and Ashanti regions, 55 56 frontline healthcare, the elderly, and persons with comorbidities. In addition to the initial doses, 57 the ministry of health received an additional supply of the AZD1222 vaccine and the Pfizer-BioNTech BNT162b2 (brand name: Tozinameran) vaccine from several high-income countries, 58 59 including Germany, Denmark, and Norway (8).

Due to the limited availability of doses and vaccine hesitancy, only 9.2% of the Ghanaian population of 30,800,000 was fully vaccinated as of December 2021 (9). Hence, the government's goal to reach widespread vaccine coverage by October 2021 was not met (6). Studies on COVID-19 vaccine hesitancy among Ghanaians reported that more than 35% of participants said they would not receive the vaccine because of concerns about vaccine efficacy and conspiracy theories (7, 10). Moreover, a seroprevalence study found that 19% of Ghanaians tested positive to anti66 SARS-CoV-2 IgM or IgG or both in August 2020 (*11*). Thus, a majority of Ghanaians may be 67 susceptible, and insight to effectively prioritize dispensation of limited vaccines would be the best 68 approach to mitigating the pandemic. To optimize Ghana's vaccination strategy and provide 69 evidence of the benefits of vaccination and increase uptake in the population, we need to quantify 70 the vaccine's impact on the magnitude of the epidemic peak, cumulative infections, and deaths 71 due to limited vaccine supplies and logistical reasons.

72 Several mathematical modeling studies on COVID-19 vaccination strategies in other jurisdictions 73 were published in 2020-21 (12-18). Alagoz and colleagues used an agent-based model to simulate 74 the transmission dynamics of COVID-19, accounting for the proportion of the population vaccinated, vaccine capacity, and adherence to nonpharmaceutical interventions (12). Moghadas 75 76 et al. used an agent-based model to evaluate the impact of vaccination campaigns on reducing the 77 incidence, hospitalizations, and death (15). Aside from agent-based models, homogenous-mixing and age-stratified compartmental models have also been used. Matrajt et al. used an age-stratified 78 deterministic model paired with optimization algorithms for sixteen age groups by varying 79 80 vaccination efficacy and coverages in the population (16). Mumtaz and colleagues used an age-81 stratified model to assess the vaccination rollout under different vaccination coverages accounting 82 for the decline in transmission and age-mixing matrix (17). Bubar et al. expanded their work further to account for contact structure, seroprevalence, and age-specific vaccine efficacy (18). 83 84 The outcomes explored in these studies include symptomatic infections, cumulative infections and 85 deaths, and hospitalizations, focusing mainly on high-income countries outside Africa. Thus, the question of who to vaccinate first when vaccines are available, and the sensitivity of modeling 86 87 outputs to the choice of contact matrices are under-explored in the African context and Ghana 88 specifically.

The purpose of this study is to use an age-stratified model to assess the impact of vaccinating one million persons in three versus six months using two African contact matrices. We retrospectively assessed the counterfactual impact of various age-targeted vaccine optimization strategies against the initial and delta strains of SARS-CoV-2 when vaccines first became available. The study's findings would facilitate future vaccination programs by identifying relevant factors to be considered to achieve the best outcomes.

#### 95 Methods

# 96 Model formulation

97 We proposed an age-stratified Susceptible-Exposed-Presymptomatic-Symptomatic-98 Asymptomatic-Recovered-Dead-Vaccinated (SEPIARD-V) model to simulate SARS-CoV-2 99 transmission dynamics and the impact of various vaccination scenarios (Figure S1 in Technical 100 Appendix A) (19). The SEPIARD-V model acknowledges that individuals who are initially 101 asymptomatic and later develop symptoms transmit the virus while in the presymptomatic phase. 102 Individual studies included in a systematic review on the transmission dynamics provided evidence 103 of the presymptomatic transmission of COVID-19 1-3 d before symptom onset (20). The model 104 was suitable for studying the transmission dynamics of COVID-19 in Ghana due to the growing 105 evidence that both symptomatic and asymptomatic patients transmit the infection regardless of 106 their symptomatic status (21-23). Our model, therefore, assumed that presymptomatic, 107 asymptomatic, and symptomatic individuals contributed to transmission. The model also assumed that immunity from both natural infection and vaccination waned over time, making reinfection 108 possible (see Table 1 and Technical Appendix A for model parameters). A basic reproduction 109 110 number  $(R_0)$  of 3.13 was assumed for the virus in the main analysis to represent the virus strain 111 that first hit Ghana in spring of 2020, referred to as the "initial strain" in this study (24). A higher

- 112 R<sub>0</sub> at 5.35 was assumed for the delta variant in the scenario analyses with a reduced vaccine
- 113 efficacy of 67% for the AZD1222 vaccine (25, 26).
- 114 The model was run for 500 d to allow enough time for the first wave of the epidemic to subside
- and observe when the second wave began to emerge.

## 116 Age groups and contact matrices

Due to the strong evidence of assortative mixing between age groups in Sub-Saharan Africa (27, 117 118 28), a contact matrix between age groups was incorporated into the model. The population was 119 stratified into three groups: <25 y, 25-64 y, and 65+ y, and two contact matrices were adapted from 120 studies in Uganda ("main matrix") and Ethiopia ("second matrix") (27, 29). Briefly, the "main 121 matrix" suggested that, on average, the within-group contact rate among individuals below 25 y 122 was 23.58 per day; for those between 25-64 y, it was 15.05 per day; and it was 0.54 per day for those above 64 y (27). For the second matrix, on average, the within-group daily contact rate 123 among individuals below 25 y was 8.2; for those between 25-64 y, it was 7.8; and it was 1.6 for 124 125 those above 64 y (29). The model was parameterized to the Ghanaian population, with 56.08% <25 y (n=17,248,000), and 4.44% 65+ y (n=1,367,520) (30). See Technical Appendix A for details. 126

### 127 Scenario analyses

This analysis aimed to determine which age group should be prioritized in the case of limited vaccine supply under different rollout speeds. We analyzed the following scenarios of the percentage of each sub-population vaccinated when prioritizing different age groups, with coverage calculated for one million people using the 2021 population (*31*): (i) 73.8% of the 65+ y, (ii) 8.2% of those between 25-64 y, (iii) 5.8% of persons below 25 y, and (iv) 3.4% of persons below 65 y would be vaccinated in each sub group; (v) we also assessed the impact of vaccinating each age group at the same rate without prioritization. Two rollout speeds (daily vaccination rates)

were used in each scenario, assuming two million doses can be exhausted in three months and six months. Details of the daily vaccination rates (v) for each scenario can be found in Tables S1-S3 in Technical Appendix A.

Finally, we performed analysis for two additional scenarios by changing the assumptions on vaccine supplies. First, the number of people to be vaccinated was either halved or doubled. Hence, we assumed enough vaccines were available for 500,000 (one million doses) and 2,000,000 (four million doses) people. The scenario analysis described above was repeated using the second contact matrix adapted from Trentini et al. (*29*).

#### 143 Analysis

The model's system of ordinary differential equations was solved following the Runge-Kutta 4 method in the deSolve package in R version 4.1.1 (R Core Team, R Foundation for Statistical Computing, Vienna, Austria) (*32*). The number of infections and deaths averted in the general population was estimated and compared across the aforementioned scenarios. Furthermore, the percent of the population who were symptomatic at the peak, ever infected (cumulative infections), and cumulative deaths were assessed. See Technical Appendix A for methodological details and Technical Appendix B for the R code.

## 151 Ethics

The Georgia Southern University Institutional Review Board determined that this project (H20364) was exempt from full review under the non-human subjects determination (G8) according to the Code of Federal Regulations Title 45 Part 46.

# 155 Results

# Symptomatic infections at the peak under the main scenario of vaccinating one million persons

158 The following results of our main analysis assumed an R<sub>0</sub> of 3.13 for the initial strain. The results 159 showed that vaccinating one million individuals <65 years in 3 months were associated with the 160 lowest percentage (6.78%) of symptomatic individuals in the population at the peak. However, 161 prioritizing the elderly resulted in the highest percentage of symptomatic individuals (7.19%) at the peak, given a three-month rollout using the main matrix. Similar results were obtained with 162 163 the second matrix. If the rollout period was increased to six months, prioritizing persons <25 years had the lowest symptomatic percentages (7.01%) using the main matrix, while the second matrix 164 165 suggested focusing on 25-64 years was associated with the lowest symptomatic infections (6.96%) 166 (Figure 1; Tables 2 and 3).

### 167 Cumulative infections under the main scenario of vaccinating one million persons

168 Our results suggest that vaccinating persons <65 years was associated with the largest number of 169 cumulative infections averted in Ghana under the assumption of vaccinating one million people in 170 three months (2,652,484 cases), whereas vaccinating persons 65+ years was associated with the 171 smallest number averted (705,981 cases) (Figure 2). We also found that vaccinating persons <25 years should be prioritized when the population was vaccinated at a slower rate (over six months) 172 or when the vaccine supply doubled or halved (Table 2). While the results for the period of three 173 months are robust to a change in the contact matrix, a more extended period (six months) seemed 174 to be sensitive (Table 3). 175

# 176 Cumulative deaths averted under the main scenario of vaccination of one million persons

Vaccinating the elderly (65+ years) could avert over 7,000 deaths if one million people were
vaccinated over three months, assuming the main contact matrix, while over 4,000 deaths would

be averted if they were vaccinated over six months. The number of deaths prevented was the lowest when persons <25 years were prioritized in both vaccination time frames (2,171 in 3 months versus 1,157 in 6 months), assuming the main contact matrix (Figure 2). Vaccinating the elderly (65+ years) remained the best option to reduce deaths regardless of the mixing patterns (Figures 1 and 2; Tables 2 and 3).

#### 184 Varying vaccine supply to vaccinate 500,000 or two million persons

185 In contrast to the base case scenarios of vaccinating 1 million people, prioritizing persons <25 186 years was associated with the lowest percentage of cumulative infections if 500,000 or two million individuals were vaccinated in 3 or 6 months (Table 2). However, simulations using the second 187 188 matrix reported mixed results. For example, prioritizing the elderly seemed to be the best strategy for lowering cumulative infections when vaccine supplies were only enough for 500,000 people 189 (177.68% for three months and 179.54% for six months). In contrast, vaccinating each age group 190 191 at the same rate was preferred when the supply was enough to vaccinate two million persons 192 (166.10% for three months and 174.23% for six months) (Table 3). Prioritizing the elderly (65+ 193 years) remained the strategy of choice to specifically lower COVID-19 mortality for both matrices 194 (Tables 2 and 3).

# 195 Comparing outcomes for the initial and delta variants in the absence of vaccination

In the absence of vaccination, the scenario analysis for the delta variant using the main matrix suggested the percentage of symptomatic persons at the peak, cumulative incidence, and deaths in the population at 10.29%, 231.24%, and 0.28%, respectively (Table S4), were higher than the initial strain at 7.26%, 174.37%, and 0.20%, respectively (Figure 1). This finding was consistent with the results from the second matrix (Table S5). In the delta variant scenario, the percentage of symptomatic individuals at the peak was slightly lower with the second matrix (10.14%) than with

202	the main matrix (10.29%). However, the cumulative infections (238.73%) and deaths (0.31%)
203	were higher with the second matrix in the delta variant scenario (Tables S4 and S5).

#### 204 Impact of vaccination strategies on symptomatic infections at the peak due to the delta 205 variant

The vaccine prioritization findings for the delta variant scenario found that prioritizing persons 206 <25 years was associated with the lowest percentage of symptomatic infections at the peak 207 regardless of the available vaccine doses and rollout speed, using the main matrix (Table 4). Like 208 the initial strain scenario, prioritizing persons <65 years was associated with the lowest percentage 209 210 of symptomatic infections at the peak (9.87%) under the assumption of vaccinating one million

211 persons over three months using the second matrix for the delta variant (Table 5).

#### Impact of vaccination strategies on cumulative infections due to the delta variant 212

The scenario where one million people were vaccinated over three months suggested that focusing 213

214 on persons <65 years had the lowest value of cumulative infections (226.25%) for the delta variant,

215 like the initial strain (165.76%). Moreover, prioritizing persons below 25 years was the best option

to minimize cumulative infections in the population with a 6-month rollout for the delta variant 216

(228.77%) (Table 4). Importantly, the results on cumulative infections of the second matrix 218 suggested the elderly (235.12%) should be prioritized for vaccination first for the delta variant

219 with a 6-month rollout (Table 5).

#### 220 Impact of vaccination strategies on cumulative deaths due to the delta variant

221 Prioritizing the elderly remained the best strategy for lowering deaths in the population for the 222 initial strain and the delta variant in all the scenarios (Tables 4, 5, S4, and S5).

#### 223 Discussion

224 Vaccination is the best tool to control the spread of SARS-CoV-2 and minimize the burden of 225 COVID-19 globally. As Ghana relies primarily on multilateral donations for their COVID-19 vaccine supply, there is a need to determine the best vaccine optimization strategies to minimize 226 227 deaths, cumulative case counts, or epidemic peaks over a relatively short period. Using two contact 228 matrices, this study utilized an age-stratified mathematical model to answer the question "who should get vaccinated first?" when the vaccine supply was limited and when supplies were 229 exhausted over three and six months. The findings suggest that, for both the initial strain and the 230 231 delta variant, prioritizing persons <65 for vaccination would avert the most cumulative infections 232 while prioritizing the elderly (65+ years) was associated with the lowest death counts.

233 Optimization of vaccine prioritization strategy is sensitive to the population structure. The finding 234 of prioritizing younger persons to avert cumulative infections has been reported in other studies 235 (18, 33, 34). Bubar and colleagues concluded in their multi-country research that the cumulative incidence of COVID-19 was lowest when adults between 20-49 years were prioritized, especially 236 with a highly-effective transmission-blocking vaccine (18). In Senegal, Diarra and colleagues used 237 238 an age-structured dynamic mathematical model to explore various vaccination strategies and 239 reported that prioritizing persons 60 years and below was associated with the lowest case burden 240 (35). The authors argued that countries with younger populations, like Ghana, should prioritize 241 vaccinating younger persons to minimize hospital costs and productivity loss.

Similar to our findings, these studies also concluded that prioritizing the elderly was associated with the lowest mortality. Regardless, Bubar and colleagues reported that persons between 20-49 years should be prioritized to minimize mortality when the transmission was low, vaccine efficacy was lower in older adults, and when the vaccine had a high effect in blocking transmission. Buckner and colleagues also reported similar results to our study and found that to control deaths

directly, the elderly should be vaccinated first after stratifying young adults by essential worker 247 248 status (36). Although the conclusions in both studies were similar, Buckner and colleagues used a dynamic approach in modeling vaccine allocation strategies that accounted for changes in the 249 250 epidemiologic status of the population ("shares of the population in different disease states") over 251 six months using stochastic nonlinear programming techniques. Similar to our findings, in their 252 vaccine optimization modeling study in India, Foy and colleagues concluded that prioritizing older adults (i.e., 60+ years) was associated with the most significant reduction in deaths regardless of 253 254 vaccine efficacy, control measures, and rollout speed (33). Another modeling study by Chapman 255 and colleagues using COVID-19 data from California reported similar results (37). However, in 256 the Chapman study, they focused on identifying the groups to prioritize after healthcare workers 257 and long-term facility residents received initial vaccine doses.

The differences in outcomes between the contact matrices may be due to the significantly lower reported contact rates among the younger population in the matrix adapted from Trentini et al. (i.e., "second matrix") (29). The study by Bubar and colleagues on vaccine optimization strategies across multiple countries, including South Africa, concluded the best vaccination strategy depended on the extent of mixing patterns (18). Future studies may consider exploring differences observed using matrices of different settings, i.e., rural versus urban and household versus community mixing.

As reported by Ko and colleagues, the question of whom to be vaccinated first also depended on the objective for vaccination (minimizing cumulative infections or deaths) and the effective reproduction number (*34*). Thus, policymakers may need to consider the compromises in deciding the best vaccine allocation strategies. For example, prioritizing the elderly may lead to fewer deaths but higher case numbers, which could exacerbate economic loss due to a high case count in a

younger population. Moreover, the transmissibility of the circulating variant may also inform the vaccine optimization strategy. However, this was not evident in our study as the priority group remained the same for the delta variant with a higher reproduction number. As found in some of our scenario analyses, other studies concluded vaccine optimization also depended on the vaccine supply (*37*, *38*).

275 Although this study has demonstrated the need to prioritize certain age groups to minimize the 276 burden of COVID-19 in Ghana depending on the objective of the program, other factors need to be considered to ensure people receive vaccinations when they become eligible. It might be 277 278 imperative to adopt targeted vaccine campaigns to minimize hesitancy in the group to be 279 prioritized. For example, Acheampong and colleagues reported the level of reluctance among older 280 adults was lower compared to younger adults in Ghana (39). Likewise, a survey among persons 281 >65 years in the US also found that 91% of the elderly were willing to get vaccinated (40). Given the reported vaccine hesitancy by age group, there is a need for campaigns to create an enabling 282 environment and engage the younger population about their role in mitigating the pandemic. 283

284 Our study has several limitations. First, our model was age-stratified only. Other demographic 285 variables (e.g., occupation and comorbidity) may change one's COVID-19 infection risk and 286 clinical prognosis (41). Second, the model did not include a hospitalization compartment. Thus, 287 the impact of the vaccine in the context of the omicron variant with demonstrated effectiveness against severe infections but modest effectiveness against infection could not be studied. Third, 288 the contact matrices used were adapted from other African countries. These countries had similar 289 demographic distributions as Ghana, and we assumed that the frequency of contact in the 290 291 population would be similar. Fourth, we did not have data to represent the rural and urban differences in contact matrices in Ghana. Fifth, our model design specified the symptomatic period 292

was the same for individuals who recovered from COVID-19 and those who died of it. Sixth, the highly transmissible omicron variant was not included in our study due to limited evidence of the effectiveness of vaccines against infection from the variant (*42*). Lastly, our model accounted for vaccine effectiveness against infection but did not account for the reduction of the case-fatality ratio if one was vaccinated yet infected.

298 In conclusion, we used an age-stratified compartmental model to assess the impact of various 299 COVID-19 vaccine allocation strategies in Ghana. This study reiterates the need to increase 300 vaccination rates by ensuring increased vaccine supplies and faster rollout speed. Vaccinating 301 persons <65 or <25 years was associated with the highest numbers of cumulative infections averted 302 for the initial strain and the delta variant while prioritizing persons 65+ years was associated with the lowest deaths in the population. The findings indicated that vaccine prioritization strategies in 303 304 a country are dependent on its policy objective, population structure, mixing patterns, and vaccine 305 supply.

306	First author bio: Dr. Sylvia K. Ofori graduated from Georgia Southern University with her
307	Doctor of Public Health degree with a concentration in epidemiology. Her research interests are
308	infectious disease epidemiology and mathematical modeling.

309 Author contributions: S.K.O. and I.C.H.F. conceptualized the study; S.K.O. programmed the

model in R and ran the simulations and drafted the manuscript under I.C.H.F.'s supervision. J.S.S.,

311 K.L.S., G.C., and B.J.C. provided consultation to S.K.O. and I.C.H.F. All authors edited, reviewed,

312 and approved the manuscript.

# 313 **Conflict of interest statement:**

314 Sylvia Ofori declares that she is a paid intern at Ionis Pharmaceuticals, and the financial 315 relationship does not affect the content of the article. Prof. Benjamin Cowling declares that he was 316 a consultant for Roche and Sanofi Pasteur. All other co-authors declare no competing interest.

# 317 **Funding statement:**

318 This project is not supported by any external funding agencies.

# 320 References

321 Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, evaluation and 1. treatment coronavirus (COVID-19). Statpearls [internet]: StatPearls Publishing; 2020. 322 323 2. Akande OW, Akande TM. COVID-19 pandemic: A global health burden. Niger Postgrad 324 Med J. 2020 Jul-Sep;27(3):147-55. 325 Ghana Health Service. COVID-19 Ghana's Outbreak Response Management Updates. 3. 326 2020 [cited] 2022 April 15. 2022]; Available from: https://ghanahealthservice.org/covid19/archive.php 327 Citi Newsroom. Omicron now most dominant COVID-19 variant in Ghana - WACCBIP. 328 4. 329 2022. Ofori SK, Schwind JS, Sullivan KL, Cowling BJ, Chowell G, Fung IC-H. Transmission 330 5. 331 dynamics of COVID-19 in Ghana and the impact of public health interventions. medRxiv : the 332 preprint server for health sciences. 2021. Quakyi NK, Agyemang Asante NA, Nartey YA, Bediako Y, Sam-Agudu NA. Ghana's 333 6. COVID-19 response: the Black Star can do even better. BMJ global health. 2021;6(3):e005569. 334 335 Alhassan RK, Aberese-Ako M, Doegah PT, Immurana M, Dalaba MA, Manyeh AK, et al. 7. 336 COVID-19 vaccine hesitancy among the adult population in Ghana: evidence from a pre-337 vaccination rollout survey. Tropical Medicine and Health. 2021 2021/12/16;49(1):96. 338 WHO Africa. More COVID-19 vaccines arrive in Ghana. 2021. 8. 339 9. Ghana Health Service. COVID-19 Ghana's Outbreak Response Management Updates. 2020 340 [cited] 2022 February 21. 2022]; Available from: 341 https://ghanahealthservice.org/covid19/archive.php Botwe BO, Antwi WK, Adusei JA, Mayeden RN, Akudjedu TN, Sule SD. COVID-19 342 10. vaccine hesitancy concerns: Findings from a Ghana clinical radiography workforce survey. 343 Radiography (Lond). 2021 Oct 8. 344 Quashie PK, Mutungi JK, Dzabeng F, Oduro-Mensah D, Opurum PC, Tapela K, et al. 345 11. Trends of SARS-CoV-2 antibody prevalence in selected regions across Ghana. medRxiv. 2021. 346 347 Alagoz O, Sethi AK, Patterson BW, Churpek M, Alhanaee G, Scaria E, et al. The impact 12. 348 of vaccination to control COVID-19 burden in the United States: A simulation modeling approach. 349 PloS one. 2021;16(7):e0254456. 350 McBryde ES, Meehan MT, Adegboye OA, Adekunle AI, Caldwell JM, Pak A, et al. Role 13. 351 of modelling in COVID-19 policy development. Paediatric respiratory reviews. 2020;35:57-60. Kohli M, Maschio M, Becker D, Weinstein MC. The potential public health and economic 352 14. value of a hypothetical COVID-19 vaccine in the United States: Use of cost-effectiveness 353 354 modeling to inform vaccination prioritization. Vaccine. 2021;39(7):1157-64. Moghadas SM, Vilches TN, Zhang K, Wells CR, Shoukat A, Singer BH, et al. The impact 355 15. of vaccination on coronavirus disease 2019 (COVID-19) outbreaks in the United States. Clinical 356 357 Infectious Diseases. 2021;73(12):2257-64. Matrajt L, Eaton J, Leung T, Brown ER. Vaccine optimization for COVID-19: Who to 358 16. 359 vaccinate first? Science Advances. 2021;7(6):eabf1374. Mumtaz GR, El-Jardali F, Jabbour M, Harb A, Abu-Raddad LJ, Makhoul M. Modeling the 360 17. 361 Impact of COVID-19 Vaccination in Lebanon: A Call to Speed-Up Vaccine Roll Out. Vaccines. 362 2021;9(7):697.

Bubar KM, Reinholt K, Kissler SM, Lipsitch M, Cobey S, Grad YH, et al. Model-informed
 COVID-19 vaccine prioritization strategies by age and serostatus. Science of the total
 environment. 2021;371(6532):916-21.

- 36619.University of British Columbia Department of Zoology. COVID-19 Models Lecture. 2020367[cited202011/15/2020];Availablefrom:
- 368 <u>https://www.zoology.ubc.ca/~bio301/Bio301/Lectures/Lecture1/COVID\_Models.pdf</u>
- 369 20. Savvides C, Siegel R. Asymptomatic and presymptomatic transmission of SARS-CoV-2:
  370 A systematic review. medRxiv. 2020 Jun 17:2020.06.11.20129072.
- Li Y, Shi J, Xia J, Duan J, Chen L, Yu X, et al. Asymptomatic and Symptomatic Patients
  With Non-severe Coronavirus Disease (COVID-19) Have Similar Clinical Features and
- 373 Virological Courses: A Retrospective Single Center Study. Frontiers in microbiology.
  374 2020;11:1570-.
- Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, et al. SARS-CoV-2 Viral Load in
  Upper Respiratory Specimens of Infected Patients. N Engl J Med. 2020 Mar 19;382(12):1177-9.
- Zhao H, Lu X, Deng Y, Tang Y, Lu J. COVID-19: asymptomatic carrier transmission is
  an underestimated problem. Epidemiology and infection. 2020;148:e116-e.
- Armachie J, Adom-Konadu A, Asiamah M, Dwomoh D. Impact of Partial lockdown on
  Time-Dependent Effective Reproduction Number of COVID-19 infection in Ghana: Application
  of change point analysis. Preprints. 2021.
- Pearson CA, Silal SP, Li MW, Dushoff J, Bolker BM, Abbott S, et al. Bounding the levels
  of transmissibility & immune evasion of the Omicron variant in South Africa. Epidemics. 2021.
- Bernal JL, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness
  of Covid-19 vaccines against the B. 1.617. 2 (Delta) variant. New England Journal of Medicine.
  2021.
- 27. le Polain de Waroux O, Cohuet S, Ndazima D, Kucharski AJ, Juan-Giner A, Flasche S, et
  al. Characteristics of human encounters and social mixing patterns relevant to infectious diseases
  spread by close contact: a survey in Southwest Uganda. BMC Infectious Diseases. 2018
  2018/04/11:18(1):172.
- Kiti MC, Kinyanjui TM, Koech DC, Munywoki PK, Medley GF, Nokes DJ. Quantifying
  age-related rates of social contact using diaries in a rural coastal population of Kenya. PloS one.
  2014;9(8):e104786.
- 394 29. Trentini F, Guzzetta G, Galli M, Zardini A, Manenti F, Putoto G, et al. Modeling the 395 interplay between demography, social contact patterns, and SARS-CoV-2 transmission in the
- 396 South West Shewa Zone of Oromia Region, Ethiopia. BMC medicine. 2021;19(1):1-13.
- 397 30. Central Intelligence Agency. The world factbook. 2020 [cited Jan 15, 2022]; Available 398 from: https://www.cia.gov/the-world-factbook/
- 399 31. Anaadem P. Ghana: Population Hits 30.8 Million Greater Accra Most Populous Region400 GSS. Ghana Today. 2021 September 22, 2021.
- 32. Soetaert KE, Petzoldt T, Setzer RW. Solving differential equations in R: package deSolve.
  Journal of statistical software. 2010;33.
- 403 33. Foy BH, Wahl B, Mehta K, Shet A, Menon GI, Britto C. Comparing COVID-19 vaccine
- 404 allocation strategies in India: A mathematical modelling study. International journal of infectious
- 405 diseases : IJID : official publication of the International Society for Infectious Diseases.
- 406 2021;103:431-8.

407 34. Ko Y, Lee J, Kim Y, Kwon D, Jung EJIJoER, Health P. COVID-19 vaccine priority 408 strategy using a heterogenous transmission model based on maximum likelihood estimation in the 409 Republic of Korea. 2021;18(12):6469.

410 35. Diarra M, Kebir A, Talla C, Barry A, Faye J, Louati D, et al. Non-pharmaceutical 411 interventions and COVID-19 vaccination strategies in Senegal: a modelling study. BMJ global 412 health. 2022;7(2):e007236.

- 413 36. Buckner JH, Chowell G, Springborn MR. Dynamic prioritization of COVID-19 vaccines
- 414 when social distancing is limited for essential workers. Proceedings of the National Academy of 415 Sciences 2021;118(16)
- 415 Sciences. 2021;118(16).
- 416 37. Chapman LAC, Shukla P, Rodríguez-Barraquer I, Shete PB, León TM, Bibbins-Domingo
  417 K, et al. Risk factor targeting for vaccine prioritization during the COVID-19 pandemic. Scientific
  418 Reports. 2022 2022/02/23;12(1):3055.
- 419 38. Saadi N, Chi YL, Ghosh S, Eggo RM, McCarthy CV, Quaife M, et al. Models of COVID-
- 420 19 vaccine prioritisation: a systematic literature search and narrative review. BMC Med. 2021 Dec421 1;19(1):318.
- 422 39. Acheampong T, Akorsikumah EA, Osae-Kwapong J, Khalid M, Appiah A, Amuasi JH.
  423 Examining Vaccine Hesitancy in Sub-Saharan Africa: A Survey of the Knowledge and Attitudes
  424 among Adults to Receive COVID-19 Vaccines in Ghana. Vaccines. 2021;9(8):814.
- 425 40. Nikolovski J, Koldijk M, Weverling GJ, Spertus J, Turakhia M, Saxon L, et al. Factors 426 indicating intention to vaccinate with a COVID-19 vaccine among older U.S. adults. PloS one.
- 427 2021;16(5):e0251963-e.
- 41. Dembek ZF, Schwartz-Watjen KT, Swiatecka AL, Broadway KM, Hadeed SJ,
  Mothershead JL, et al. Coronavirus Disease 2019 on the Heels of Ebola Virus Disease in West
  Africa. Pathogens (Basel, Switzerland). 2021;10(10):1266.
- 431 42. Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. Covid-19
  432 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. N Engl J Med. 2022 Mar 2.
- 433 43. Abbasi Z, Zamani I, Mehra AHA, Shafieirad M, Ibeas A. Optimal Control Design of 434 Impulsive SQEIAR Epidemic Models with Application to COVID-19. Chaos, solitons, and 435 fractals. 2020 2020-Oct;139:110054-.
- 436 44. Liu Z, Magal P, Seydi O, Webb G. A COVID-19 epidemic model with latency period.
  437 Infectious Disease Modelling. 2020;5:323-37.
- 438 45. Cai Q, Huang D, Ou P, Yu H, Zhu Z, Xia Z, et al. COVID-19 in a designated infectious
  439 diseases hospital outside Hubei Province, China. J Allergy. 2020.
- 440 46. Xing Y, Ni W, Wu Q, Li W, Li G, Tong J, et al. Prolonged presence of SARS-CoV-2 in
  441 feces of pediatric patients during the convalescent phase. medRxiv : the preprint server for health
  442 sciences. 2020.
- 443 47. Ma S, Zhang J, Zeng M, Yun Q, Guo W, Zheng Y, et al. Epidemiological parameters of
  444 coronavirus disease 2019: a pooled analysis of publicly reported individual data of 1155 cases
  445 from seven countries. MedRxiv : the preprint server for health sciences. 2020.
- 446
  48. Byrne AW, McEvoy D, Collins AB, Hunt K, Casey M, Barber A, et al. Inferred duration
  of infectious period of SARS-CoV-2: rapid scoping review and analysis of available evidence for
  asymptomatic and symptomatic COVID-19 cases. BMJ open. 2020;10(8):e039856.
- 449 49. Tindale L, Coombe M, Stockdale JE, Garlock E, Lau WYV, Saraswat M, et al.
- 450 Transmission interval estimates suggest pre-symptomatic spread of COVID-19. MedRxiv : the
- 451 preprint server for health sciences. 2020.

- 452 50. Chen M, Li M, Hao Y, Liu Z, Hu L, Wang L. The introduction of population migration to 453 SEIAR for COVID-19 epidemic modeling with an efficient intervention strategy. Information
- 454 Fusion. 2020;64:252-8.
- 455 51. Buitrago-Garcia D, Egli-Gany D, Counotte MJ, Hossmann S, Imeri H, Ipekci AM, et al.
  456 Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2
  457 infections: A living systematic review and meta-analysis. PLoS medicine. 2020;17(9):e1003346458 e.
- 459 52. Knoll MD, Wonodi C. Oxford-AstraZeneca COVID-19 vaccine efficacy. Lancet (London,
   460 England). 2021;397(10269):72-4.
- 461 53. Centers for Disease Control and Prevention. Pandemic Planning Scenarios. 2020 [cited
  462 2020 November 12, 2020]; Available from: <u>https://www.cdc.gov/coronavirus/2019-</u>
  463 <u>ncov/hcp/planning-scenarios.html</u>
- 464 54. Iacobucci G. Covid-19: Protection from two doses of vaccine wanes within six months,
  465 data suggest. British Medical Journal Publishing Group; 2021.
- 466 55. Good MF, Hawkes MT. The Interaction of Natural and Vaccine-Induced Immunity with
- 467 Social Distancing Predicts the Evolution of the COVID-19 Pandemic. Mbio. 2020;11(5).
  468 56. Lawal Y. Africa's low COVID-19 mortality rate: A paradox? International journal of
- 468 56. Lawal Y. Africa's low COVID-19 mortality rate: A paradox? International journal of 469 infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
- 470 2021;102:118-22.
- 471

# 473 Table 1: Parameter values for the age-stratified SEPIARD-V COVID-19 model

Parameter	Symbol	Value	Reference
Mean latency period which is	1/k	1.85 d	Abbasi et al., (43),
the period from exposure to			Liu et al. (44)
infectiousness			
Mean duration of being	1/f	15.7 d	Cai et al., (45) Xing et al.,
infectious and symptomatic			(46)
Mean duration of being	1/q	7.25 d	Ma et al., $(47)$ , Byrne et al.
infectious and asymptomatic			(48)
Mean duration of being	1/c	2.9 d	Tindale et al., $(49)$ ,
infectious and presymptomatic			Byrne et al., $(48)$
Reproduction number for the	R <sub>0</sub>	3.13	Armachie et al., (24)
initial strain			
Reproduction number for the	R <sub>0</sub>	5.35	Pearson et al., (25)
delta strain			
Probability of exposed person	δ	0.30	Chen et al., (50) Buitrago-
becoming pre-symptomatically			Garcia et al., $(51)$
infected			
Vaccine efficacy against	σ	0.745	Knoll et al.,
infection			(52)
			()
Relative transmissibility of	u	0.75	CDC (53)
asymptomatic individuals	u	0.75	CDC (55)
Relative transmissibility of	r	0.75	CDC (53)
presymptomatic individuals	1	0.75	CDC (55)
Mean duration of immunity	χ	182 d	Iacobucci (54)
following vaccination	r	102 u	
Mean duration of immunity	W	365 d	Good & Hawke (55)
following natural infection	vv	505 d	
Age-specific case fatality ratio	Z	0.002 for <25 y,	Our world in Data (Range
		0.002 for 25-64 y,	from January 26, 2021, and
		0.003  for  25  or  y, 0.048P  for  65+	November 12, 2021),
			Yakubu(56)
Daily vaccination rate	v	Varied between	Estimated
		0.00009 -	
		$0.0163977 \mathrm{d}^{-1} \mathrm{per}$	
		person	
	I		

# Table 2: Scenario analysis of outcomes in the total population under various vaccination scenarios using the main matrix for the initial strain

Vaccine prioritization	500,000 people vaccinated in 3 months (%)	500,000 people vaccinate d in 6 months (%)	One million people vaccinate d in 3 months (%)	One million people vaccinate d in 6 months (%)	Two million people were vaccinate d in 3 months (%)	Two million people were vaccinate d in 6 months (%)
Symptomatic infections at peak						
Only 65+	7.22	7.24	7.19	7.22	7.16	7.19
25-64	7.09	7.17	6.92	7.09	6.61	6.92
<25	7.01	7.13	6.79	7.01	6.25	6.75
< 65	7.03	7.15	6.78	7.03	6.37	6.81
Same vaccination rate across age groups	7.04	7.15	6.83	7.04	6.40	6.83
Cumulative infections						
Only 65+	172.87	173.47	172.08	172.87	171.35	172.08
25-64	170.80	172.57	167.51	170.89	161.20	167.44
<25	170.04	172.20	166.29	170.04	157.04	165.76
< 65	170.28	172.43	165.76	170.28	158.20	166.19
Same vaccination rate across age groups	170.41	172.39	166.42	170.41	158.47	166.42
Deaths						
Only 65+	0.18	0.19	0.18	0.18	0.17	0.17
25-64	0.19	0.19	0.19	0.19	0.18	0.19
<25	0.19	0.19	0.19	0.19	0.18	0.19
< 65	0.19	0.19	0.19	0.19	0.18	0.19
Same vaccination rate across age groups	0.19	0.19	0.19	0.19	0.18	0.19

480

481

# Table 3: Scenario analysis of outcomes in the total population under various vaccination scenarios using the second matrix for the initial strain

Vaccine prioritization	500,000 people vaccinated in 3 months (%)	500,000 people vaccinate d in 6 months (%)	One million people vaccinate d in 3 months (%)	One million people vaccinate d in 6 months (%)	Two million people were vaccinate d in 3 months (%)	Two million people were vaccinate d in 6 months (%)
Symptomatic infections at peak						
Only 65+	7.02	7.09	6.92	7.02	6.82	6.92
25-64	6.96	7.07	6.76	6.96	6.36	6.75
<25	6.99	7.09	6.82	6.98	6.41	6.79
< 65	6.97	7.08	6.74	6.97	6.35	6.76
Same vaccination rate across age groups	6.98	7.08	6.76	6.98	6.35	6.76
Cumulative infections						
Only 65+	177.68	179.54	175.32	177.68	173.23	175.33
25-64	178.22	180.28	174.34	178.22	166.67	174.26
<25	178.62	180.48	175.41	178.62	167.63	174.95
< 65	178.39	180.48	174.00	178.39	166.69	174.42
Same vaccination rate across age groups	178.30	180.33	174.23	178.30	166.10	174.23
Deaths						
Only 65+	0.19	0.20	0.18	0.19	0.17	0.18
25-64	0.21	0.22	0.21	0.21	019	0.21
<25	0.22	0.22	0.22	0.22	0.21	0.21
< 65	0.22	0.22	0.21	0.22	0.20	0.21
Same vaccination rate across age groups	0.21	0.22	0.21	0.21	0.20	0.21

485

486

Table 4: Comparing outcomes for the delta variant when one million persons were
 vaccinated under the various vaccination strategies using the main matrix

Vaccine	Initial strain	Delta variant	Initial strain	Delta variant
prioritization	(3 months) (%)	(3 months) (%)	(6 months) (%)	(6 months) (%)
Symptomatic infections at peak				
Only 65+	7.19	10.22	7.22	10.25
25-64	6.92	10.08	7.09	10.18
<25	6.79	10.01	7.01	10.14
< 65	6.78	10.01	7.03	10.15
Same vaccination rate across age groups	6.83	10.03	7.04	10.16
Cumulative infections				
Only 65+	172.08	228.41	172.87	229.49
25-64	167.51	227.05	170.89	229.07
<25	166.29	226.63	170.04	228.77
< 65	165.76	226.25	170.28	228.87
Same vaccination rate across age groups	166.42	226.54	170.41	228.89
Deaths				
Only 65+	0.18	0.25	0.18	0.26
25-64	0.19	0.27	0.19	0.28
<25	0.19	0.28	0.19	0.28
< 65	0.19	0.27	0.19	0.28
Same vaccination rate across age groups	0.19	0.27	0.19	0.28

490

# 492 Table 5: Comparing outcomes for the delta variant when one million persons were


# 493 vaccinated under the various vaccination strategies using the second matrix

Vaccine prioritization	Initial strain (3 months) (%)	Delta variant (3 months) (%)	Initial strain (6 months) (%)	Delta variant (6 months) (%)
Symptomatic infections at peak				
Only 65+	6.92	9.96	7.02	10.04
25-64	6.76	9.90	6.96	10.01
<25	6.82	9.91	6.98	10.01
< 65	6.74	9.87	6.97	10.01
Same vaccination rate across age groups	6.76	9.89	6.98	10.01
Cumulative				
infections				
Only 65+	175.32	232.78	177.68	235.12
25-64	174.34	234.35	178.22	236.48
<25	175.41	234.06	178.62	236.57
< 65	174.00	232.32	178.39	236.50
Same vaccination rate across age groups	174.23	234.12	178.30	236.43
Deaths				
Only 65+	0.18	0.26	0.19	0.28
25-64	0.21	0.31	0.21	0.31
<25	0.22	0.31	0.22	0.31
< 65	0.21	0.31	0.22	0.31
Same vaccination rate across age groups	0.21	0.31	0.21	0.31

502 Figure 1: The impact of various vaccination scenarios on symptomatic infections at peak

503 (upper panel), cumulative infections (middle panel), and deaths (lower panel) as a percentage

of the general population with two different contact matrices, in the main analysis with



\*% of cumulative infections is greater than 100% because of waning immunity from natural
 infection and vaccination


509

# 510 Figure 2: The impact of various vaccination scenarios on the number of cumulative infections

511 averted (upper panel) and the number of deaths averted (lower panel) in the general

512 population with two different contact matrices, in the main analysis with R<sub>0</sub>=3.13 (initial

513 strain).



# **Technical Appendix A for:**

## Modeling infections and deaths averted due to COVID-19 vaccination strategies in Ghana

Sylvia K. Ofori,<sup>1</sup> Jessica S. Schwind,<sup>2</sup> Kelly L. Sullivan,<sup>1</sup> Benjamin J. Cowling,<sup>3</sup> Gerardo Chowell,<sup>4</sup> Isaac Chun-Hai Fung<sup>1</sup>\*

# Affiliations:

1 Department of Biostatistics, Epidemiology and Environmental Health Sciences, Jiann-

Ping Hsu College of Public Health, Georgia Southern University.

2 Institute of Health Logistics and Analytics, Georgia Southern University.

3 WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of

Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong.

4 Department of Population Health Sciences, School of Public Health, Georgia State University

\*Correspondence should be addressed to Isaac Chun-Hai Fung, Ph.D., P.O. Box 7989,

Department of Biostatistics, Epidemiology and Environmental Health Sciences, Jiann-Ping Hsu

College of Public Health, Georgia Southern University, Statesboro, GA 30458-7989, USA.

Email: cfung@georgiasouthern.edu. Tel: +1 912 4785079.

# **Supplementary Text: Methods**

# **Model equations**

The total population of Ghana, N, is assumed to be a constant and equals the sum of the compartments representing individuals with different disease statuses (including COVID-19-specific deaths) at any time during the simulation and that births and deaths from natural (non-COVID-19) causes do not affect the infection dynamics in the population:

$$N = S + E + P + I + A + R + V + D$$
 (Eq. 1)

Following the assumption of a frequency-dependent model, we define the force of infection,  $\lambda$ , as a combination of infection terms with symptomatic, asymptomatic, and pre-symptomatic individuals, each contributing to the transmission process as follows:

$$\lambda = \frac{\beta(I+uA+rP)}{N}$$
 (Eq. 2),

where the contributions of asymptomatic and presymptomatic individuals are fractions u and r of that of the symptomatic individuals.

The set of ordinary differential equations (ODE) that defines the progression of susceptible individuals through different disease statuses upon infection and a vaccinated and immune status upon vaccination and their re-entry into the susceptible state due to waning immunity is described below:

$$dS/dt = (-\lambda S) + wR - (v\sigma S) + \chi V \qquad (Eq. 3)$$

$$dE/dt = \lambda S - kE \tag{Eq. 4}$$

$$dP/dt = \delta kE - cP \tag{Eq. 5}$$

$$dI/dt = cP - (1-z)fI - zfI$$
 (Eq. 6)

$$dA/dt = (1 - \delta)kE - qA$$
 (Eq. 7)

$$dR/dt = (1-z)fI + qA - wR$$
 (Eq. 8)

$$dD/dt = zfI (Eq. 9)$$

$$\frac{dV}{dt} = v\sigma S - \chi V \tag{Eq. 10}$$

$$dC/dt = kE (Eq. 11)$$

In the SEPIARD-V model, the population is initially susceptible until an infectious individual is introduced. After contact with an infectious person, susceptible individuals are infected at a rate of  $\lambda$  (force of infection). While in the latent period (E), they do not transmit the virus. Individuals leave the latent period at a rate of k and can either become asymptomatically (A) or presymptomatically infectious (P). Asymptomatic individuals will recover (move to the R compartment) at a rate of q without showing any symptoms (1, 2). Pre-symptomatic infectious individuals become symptomatic (I) at a rate of c. The mean duration of the symptomatic period is defined as 1/f. A fraction z of symptomatic individuals will die from COVID-19 (move to the D compartment) while the other fraction (1-z) will recover (move to the R compartment). Susceptible individuals become fully vaccinated (move to the V compartment) at a rate of v per day, while the vaccine is assumed to have an efficacy (or effectiveness) of  $\sigma$ .

#### **Model parameters**

In our model, after susceptible individuals are exposed, the latent period, which is the period from exposure to infectiousness, is 1/k and is assumed to have a mean of 1.85 days (3, 4). Once exposed, a third ( $\delta$ ) of individuals become pre-symptomatically infected, and the rest (1- $\delta$ ) become asymptomatic (5, 6). The mean pre-symptomatic period, 1/c, is assumed to be 2.9 (7). The mean duration of infectiousness for symptomatic individuals (1/f) is 15.7 days, and that of asymptomatic

individuals (1/q) is 7.25 days (8-11). The transmission rate,  $\beta$ , is estimated from the basic reproduction number (R<sub>0</sub>) using the formula  $(1 - \delta) \left(\frac{u\beta}{q}\right) + \delta \left(\frac{r\beta}{c} + \frac{\beta}{f}\right) (12)$ , assuming a value of 3.13 for the initial strain as assessed by Armachie and colleagues (13). This value would be updated in our scenario analysis of the delta variant. According to the CDC COVID-19 pandemic planning scenarios, the relative transmissibility of asymptomatic and pre-symptomatic individuals, *u* and *r*, are assumed to be 0.75, respectively (14). Two doses of the AstraZeneca COVID-19 vaccine were reported to have an efficacy ( $\sigma$ ) of 0.745 (15). This value would also be updated in our scenario analysis of the delta variant. Immunity is acquired from either natural infection or vaccination. Vaccination-induced immunity offers protection from infection for six months (180 days) and wanes at a rate of  $\chi$ , while that from natural infection, *w*, is about one year (365 days) (16). The rate of vaccination, *v*, is varied depending on the scenario. Once immunity wanes, individuals move back to the susceptible compartment. Details of model parameters are found in Table 1.

#### Age-stratification

The aforementioned SEPIARD-V model was further developed into an age-stratified model.

The idea of the age-stratified model was adapted from a modeling study by Keeling and White on vaccination strategies with an optimal number of cases and severity effects during Britain's 2009 H1N1 influenza pandemic (*17*). Our analysis would answer research questions similar to the Keeling and White study and include modifications to address issues pertinent to the COVID-19 pandemic in Ghana. With vaccine supplies available, policymakers would be interested in which epidemiological goal the vaccine would most impact.

A recent retrospective cohort study in Ghana by Ashninyo et al. reported that COVID-19 disproportionately affected the younger population with a mean age of 37.9 years, with the

majority (56.64%) between 31 and 64 years (18). According to Ghana's demographics, 56.08 % of the population is below 25 years, and 4.44% are 65 years or above (19). Therefore, the population was stratified into three groups: <25 years, 25-64 years, and 65+ years.

## Age-stratified model formulation

An age-stratified compartmental model assumes that population mixing is not homogeneous and the numbers of contact between members of age groups follow a specified contact matrix. The number of secondary cases caused by an infectious individual in a totally susceptible population is commonly known as the basic reproduction number. In the context of a heterogeneous-mixing model, the basic reproduction number is also known as a basic reproductive ratio and is the largest eigenvalue of the next generation matrix (NGM) (20). Following the work of Towers and Feng (21), the reproduction number of an age-stratified model is equal to the product of the transmission coefficient  $\beta$ , the mean duration of infectiousness, and the largest eigenvalue of a matrix M that is defined by its elements  $M_{ij} = C_{ij} \left(\frac{N_i}{N_j}\right)$ , where C<sub>ij</sub> is the contact matrix, and N<sub>i</sub> and N<sub>j</sub> are the numbers of individuals in age groups i and j respectively (22).

#### **Contact matrices used**

Due to the strong evidence of assortative mixing between age groups in the general population of Uganda (23) and Kenya (24), the contact matrix of the population was considered in the modeling of vaccination allocation strategies in Ghana. As reported by Waroux and colleagues, the contact patterns of Uganda were adopted in this study because their matrix corresponds to the population groups used in this study (below 25 years, 25-64 years, and 65 years or above). There is also a similarity in the proportion of age structure between Uganda and Ghana. Waroux and colleagues used the survey method to study the contact patterns of residents in rural Uganda in 2014 and

found that, on average, the within-group contact rate among individuals below 25 years is 23.58 per day; for those between 25-64 years, it was 15.05 per day and 0.54 per day for those above 64 years (23).

Therefore, the 3 by 3 contact matrix is:

	Below 25 years	25-64 years	65 years and above
Below 25 years	23.58	9.31	0.87
25-64 years	13.01	15.05	1.53
65 years and above	2.29	2.44	0.54

This contact matrix was corrected for reciprocity using methods described by Melegaro et al. in their study in Zimbabwe (25).

The second matrix was adapted from a study in Ethiopia by Trentini et al., who also used surveytype interviews to estimate age-specific patterns (*26*). The contact matrix was used due to the similar population structure to Ghana. Furthermore, the data on contact patterns were collected in 2019, prior to the COVID-19 pandemic, and may reflect recent contact rates. On average, the within-group contact rate among individuals below 25 years is 8.2 per day; for those between 25-64 years, it was 7.8 per day, and 1.6 per day for those above 64 years (*23*). The 3 by 3 contact matrix is:

	Below 25 years	25-64 years	65 years and above
Below 25 years	8.2	5	1
25-64 years	2	7.8	2.8
65 years and above	0.1	2.2	1.6

This contact matrix was then corrected for reciprocity using methods described by Melegaro in their study in Zimbabwe (27).

### Case-fatality ratio in the age-stratified model

The age-specific fatality ratios were calculated using data from Odikro and colleagues' study on the epidemiology of COVID-19 outbreak in Ghana (28). Using the total number of cases reported in their study (n=17,763) and the percentage of cases reported in each 10-year age group as of June 30, 2020, we calculated the percentage of cases in each age group as 23.85% for persons below 25 years, 70.65% for those between 25-64 years and 5.5% for 65+ years. For the cases reported among persons 20-29 years, we assumed that half of them occurred in persons between 20-24 years, and the other half occurred in those between 25-29 years. Next we calculated the expected number of cases for <25 years (n=4,236), 25-64 years (n=12,550) and elderly (n=977). The expected number of deaths was estimated for each age group assuming that 9% of the total deaths (n=117) deaths occurred among <25 years, 51% for 25-64 years and, 40% among the elderly (65+) (28, 29). Finally, we calculated the age-specific case fatality ratios as the ratio between the number of deaths in each age group by the number of cases in each age group. Hence, the estimates were 0.002 for <25 years, 0.005 for 25-64 years and 0.048 for 65+ years. All other variables except the vaccination rate remained the same as described in Table 1.

#### **Model initialization**

The model's system of ODE was solved following the Runge-Kutta 4 method in the deSolve package in R version 4.1.1 (*30*). To keep it simple, the population size of Ghana, N, was set to 30,800,000. We also assumed that for the base case scenario, at the beginning of the simulation, I

=1, A=0, P=0, D=0, and V=0. We accounted for the age-specific seroprevalence of SARS-CoV-2 using estimates from Quarshie and colleagues in August 2020 (*31*). We, therefore, assumed that 17.5% of persons below 25 years, 43.6% of those between 25-64 years, and 18% of 65+ persons had been infected at the beginning of the simulation. These individuals were moved to the recovery compartment at the beginning of the simulation. The model was run for 500 days to allow enough time for the first wave of the epidemic to die out and observe when the second wave began to emerge.

# Outcomes

The cumulative number of infections and deaths averted in the general population was estimated and compared for each scenario. Furthermore, the percent of the population who were symptomatic at the peak, ever infected (cumulative infections), and cumulative deaths were assessed. The percentage of cumulative infection could exceed 100% because as immunity waned, individuals would become susceptible again to repeated infections.

## R code

The R code used for simulation in this study is provided in Technical Appendix B.

# Table S1: Daily vaccination rates for vaccinating one million people in three months and six months using an age-stratified model

Scenario	Fraction of total population	Number in each subgroup	1 million people can be vaccinated, % of the subpopulation vaccinated	The daily vaccination rate for a campaign of 3 months	The daily vaccination rate for a campaign of 6 months
Only 65+ y	0.044	1,355,200	73.8%	0.008199	0.00410
25-64 y	0.396	12,196,800	8.2%	0.000911	0.00046
<25 y	0.56	17,248,000	5.8%	0.000644	0.00032
<65 y	0.956	29,444,800	3.4%	0.000377	0.00019
Same vaccination rate	1	30,800,000	3.2%	0.000361	0.00018

Table S2: Daily vaccination rates for	vaccinating 500,000	people in three	months and six
months using an age-stratified model			

Scenario	Fraction of total population	Number in each subgroup	500,000 people can be vaccinated, % of the subpopulation vaccinated	The daily vaccination rate for a campaign of 3 months	The daily vaccination rate for a campaign of 6 month
Only 65+ y	0.044	1,355,200	36.9%	0.004099436	0.00205
25-64 y	0.396	12,196,800	4.1%	0.000455493	0.00023
<25 y	0.56	17,248,000	2.9%	0.000322099	0.00016
<65 y	0.956	29,444,800	1.7%	0.000188677	0.00009
Same vaccination rate	1	30,800,000	1.6%	0.000180375	0.00009

# Table S3: Daily vaccination rates for vaccinating two million people in three months and six months using an age-stratified model

Scenario	Fraction of total population	Number in each subgroup	2 million people can be vaccinated, % of the subpopulation vaccinated	The daily vaccination rate for a campaign of 3 months	The daily vaccination rate for a campaign of 6 months
Only 65+ y	0.044	1355200	147.6%	0.0163977	0.00819887
25-64 y	0.396	12196800	16.4%	0.001822	0.00091099
<25 y	0.56	17248000	11.6%	0.0012884	0.0006442
<65 y	0.956	29444800	6.8%	0.0007547	0.00037735
Same vaccination rate	1	30800000	6.5%	0.0007215	0.00036075

Table S4: Sensitivity analysis of outcomes in the total population under various vaccination scenarios using the main matrix for the delta variant. If there were no vaccination, 10.29% of the population would be symptomatic at the epidemic peak, there would be a total of 231.24% cumulative incidence, and 0.28% of the population would die of COVID-19.

Vaccine prioritization (years) Symptomatic infections at peak	500,000 people were vaccinate d in 3 months (%)	500,000 people were vaccinate d in 6 months (%)	One million people were vaccinate d in 3 months (%)	One million people were vaccinate d in 6 months (%)	Two million people were vaccinate d in 3 months (%)	Two million people were vaccinate d in 6 months (%)
Only 65+	10.25	10.27	10.22	10.25	10.18	10.22
25-64 <25	10.18	10.24 10.21	10.08	10.18	9.89 9.68	10.09 9.99
< 65	10.14	10.21	10.01	10.14	9.08	9.99
Same vaccination rate	10.15	10.22	10.03	10.16	9.78	10.02
Cumulative infections						
Only 65+	229.49	230.23	228.41	229.49	227.22	228.41
25-64	229.07	230.15	227.05	229.07	223.02	227.00
<25	228.77	230.00	226.63	228.77	221.33	226.32
< 65	228.87	230.11	226.25	228.87	221.89	226.50
Same vaccination rate	228.89	230.06	226.54	228.89	221.87	226.54
Deaths						
Only 65+	0.26	0.27	0.25	0.26	0.23	0.25
25-64	0.28	0.28	0.27	0.28	0.27	0.27
<25	0.28	0.28	0.28	0.28	0.27	0.28
< 65	0.28	0.28	0.27	0.28	0.27	0.27
Same vaccination rate	0.28	0.28	0.27	0.28	0.27	0.27

Table S5: Sensitivity analysis of outcomes in the total population under various vaccination scenarios using the second matrix for the delta variant. If there were no vaccination, 10.14% of the population would be symptomatic at the epidemic peak, there would be a total of 238.73% cumulative incidence, and 0.31% of the population would die of COVID-19.

Vaccine prioritization	500,000 people were vaccinat ed in 3 months (%)	500,000 people were vaccinate d in 6 months (%)	One million people were vaccinate d in 3 months (%)	One million people were vaccinate d in 6 months (%)	Two million people were vaccinate d in 3 months (%)	Two million people were vaccinate d in 6 months (%)
Symptomatic infections at peak						
Only 65+	10.04	10.09	9.96	10.04	9.85	9.96
25-64 <25	10.01	10.08	9.90	10.01	9.66	9.89 9.89
< 65	10.01	10.08 10.08	9.91 9.87	10.01 10.01	9.64 9.64	9.89
Same vaccination rate	10.01	10.08	9.89	10.01	9.64	9.89
Cumulative						
infections Only 65+	235.12	236.68	232.78	235.12	230.20	232.78
25-64	236.47	230.08	232.78	236.48	230.20	232.78
<25	236.57	237.65	234.71	236.57	230.05	234.44
< 65	236.51	237.67	234.06	236.51	229.99	234.29
Same vaccination rate	236.43	237.58	234.12	236.43	229.52	234.12
Deaths						
Only 65+	0.28	0.30	0.26	0.28	0.24	0.26
25-64	0.31	0.31	0.31	0.31	0.30	0.31
<25	0.31	0.31	0.31	0.31	0.31	0.31
< 65	0.31	0.31	0.31	0.31	0.30	0.31
Same vaccination rate	0.31	0.31	0.31	0.31	0.30	0.31

## References

1. Liu R, Leung RK-k, Chen T, Zhang X, Chen F, Chen S, et al. The Effectiveness of Age-Specific Isolation Policies on Epidemics of Influenza A (H1N1) in a Large City in Central South China. PLoS One. 2015;10(7):e0132588.

2. Zhao Z-Y, Zhu Y-Z, Xu J-W, Hu S-X, Hu Q-Q, Lei Z, et al. A five-compartment model of age-specific transmissibility of SARS-CoV-2. Infectious Diseases of Poverty. 2020 2020/08/26;9(1):117.

3. Abbasi Z, Zamani I, Mehra AHA, Shafieirad M, Ibeas A. Optimal Control Design of Impulsive SQEIAR Epidemic Models with Application to COVID-19. Chaos, Solitons & Fractals. 2020 2020/10/01/;139:110054.

4. Liu Z, Magal P, Seydi O, Webb G. A COVID-19 epidemic model with latency period. Infectious Disease Modelling. 2020;5:323-37.

5. Chen M, Li M, Hao Y, Liu Z, Hu L, Wang L. The introduction of population migration to SEIAR for COVID-19 epidemic modeling with an efficient intervention strategy. Information Fusion. 2020;64:252-8.

6. Buitrago-Garcia D, Egli-Gany D, Counotte MJ, Hossmann S, Imeri H, Ipekci AM, et al. Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis. PLoS Med. 2020;17(9):e1003346.

7. Tindale L, Coombe M, Stockdale JE, Garlock E, Lau WYV, Saraswat M, et al. Transmission interval estimates suggest pre-symptomatic spread of COVID-19. medRxiv. 2020.

8. Cai Q, Huang D, Ou P, Yu H, Zhu Z, Xia Z, et al. COVID-19 in a designated infectious diseases hospital outside Hubei Province, China. Allergy. 2020;75(7):1742-52.

9. Byrne AW, McEvoy D, Collins AB, Hunt K, Casey M, Barber A, et al. Inferred duration of infectious period of SARS-CoV-2: rapid scoping review and analysis of available evidence for asymptomatic and symptomatic COVID-19 cases. BMJ open. 2020;10(8):e039856.

10. Thiruvengadam G, Ramanujam R, Marappa L. Modeling the recovery time of patients with coronavirus disease 2019 using an accelerated failure time model. Journal of International Medical Research. 2021;49(8):03000605211040263.

11. Xing Y-H, Ni W, Wu Q, Li W-J, Li G-J, Wang W-D, et al. Prolonged viral shedding in feces of pediatric patients with coronavirus disease 2019. Journal of microbiology, immunology

infection. 2020;53(3):473-80.

University of British Columbia Department of Zoology. COVID-19 Models Lecture.
 [cited 2020 11/15/2020]; Available from:

https://www.zoology.ubc.ca/~bio301/Bio301/Lectures/Lecture1/COVID\_Models.pdf

13. Armachie J, Adom-Konadu A, Asiamah M, Dwomoh D. Impact of Partial lockdown on Time-Dependent Effective Reproduction Number of COVID-19 infection in Ghana: Application of change point analysis. Preprints. 2021.

14. Centers for Disease Control and Prevention. Pandemic Planning Scenarios. 2020 [cited 2020 November 12, 2020]; Available from: <u>https://www.cdc.gov/coronavirus/2019-ncov/hcp/planning-scenarios.html</u>

15. Knoll MD, Wonodi C. Oxford-AstraZeneca COVID-19 vaccine efficacy. Lancet. 2021;397(10269):72-4.

16. Good MF, Hawkes MT. The Interaction of Natural and Vaccine-Induced Immunity with Social Distancing Predicts the Evolution of the COVID-19 Pandemic. Mbio. 2020;11(5).

17. Keeling MJ, White PJ. Targeting vaccination against novel infections: risk, age and spatial structure for pandemic influenza in Great Britain. Journal of the Royal Society Interface. 2011;8(58):661-70.

18. Mary Eyram Ashinyo VD, Stephen Dajaan Dubik, Kingsley Ebenezer Amegah, Selorm Kutsoati, Ebenezer Oduro-Mensah, Peter Puplampu, Martha Gyansa-Lutterodt, Delese Mimi Darko, Kwame Ohene Buabeng, Anthony Ashinyo, Anthony Adofo Ofosu, Nyonuku Akosua Baddoo, Samuel Kaba Akoriyea, Francis Ofei, Patrick Kuma-Aboagye. Clinical characteristics, treatment regimen and duration of hospitalization among COVID-19 patients in Ghana: a retrospective cohort study. Pan African Medical Journal. 2020;2(PAMJ Special issue on COVID 19 in Africa).

19. Factbook CIA. The world factbook. See also: <u>https://www</u> cia gov/library/publications/the-world-factbook. 2020.

20. Anderson RM, May RM. Infectious diseases of humans: dynamics and control: Oxford university press; 1992.

21. Towers S, Feng Z. Social contact patterns and control strategies for influenza in the elderly. Mathematical biosciences. 2012;240(2):241-9.

22. Towers S. SIR infectious disease model with age classes. 2012 [cited 2021 09/15/2021]; Available from: <u>http://sherrytowers.com/2012/12/11/sir-model-with-age-classes/</u>

23. le Polain de Waroux O, Cohuet S, Ndazima D, Kucharski AJ, Juan-Giner A, Flasche S, et al. Characteristics of human encounters and social mixing patterns relevant to infectious diseases spread by close contact: a survey in Southwest Uganda. BMC Infect Dis. 2018 2018/04/11;18(1):172.

24. Kiti MC, Kinyanjui TM, Koech DC, Munywoki PK, Medley GF, Nokes DJ. Quantifying age-related rates of social contact using diaries in a rural coastal population of Kenya. PLoS One. 2014;9(8):e104786.

25. Melegaro A, Jit M, Gay N, Zagheni E, Edmunds WJ. What types of contacts are important for the spread of infections? Using contact survey data to explore European mixing patterns. Epidemics. 2011;3(3-4):143-51.

26. Trentini F, Guzzetta G, Galli M, Zardini A, Manenti F, Putoto G, et al. Modeling the interplay between demography, social contact patterns, and SARS-CoV-2 transmission in the South West Shewa Zone of Oromia Region, Ethiopia. BMC medicine. 2021;19(1):1-13.


27. Melegaro A, Del Fava E, Poletti P, Merler S, Nyamukapa C, Williams J, et al. Social contact structures and time use patterns in the Manicaland Province of Zimbabwe. PLoS One. 2017;12(1):e0170459.

28. Odikro MA, Kenu E, Malm KL, Asiedu-Bekoe F, Noora CL, Frimpong J, et al.
Epidemiology of COVID-19 outbreak in Ghana, 2020. Ghana Med J. 2020;54(4s):5-15.
29. Lawal Y. Africa's low COVID-19 mortality rate: A paradox? Int J Infect Dis.
2021;102:118-22.

30. Soetaert KE, Petzoldt T, Setzer RW. Solving differential equations in R: package deSolve. Journal of statistical software. 2010;33.

31. Quashie PK, Mutungi JK, Dzabeng F, Oduro-Mensah D, Opurum PC, Tapela K, et al. Trends of SARS-CoV-2 antibody prevalence in selected regions across Ghana. medRxiv. 2021.

Figure S1: The Susceptible-Exposed-Presymptomatic-Symptomatic-Asymptomatic-Recovered-Dead-Vaccinated (SEPIARD-V) model represents SARS-CoV-2 transmission and COVID-19 disease progress and the vaccination against COVID-19.



# Technical Appendix B for: Modeling infections and deaths averted due to COVID-19 vaccination strategies in Ghana

Sylvia K. Ofori, Jessica S. Schwind, Kelly L. Sullivan, Gerardo Chowell, Benjamin J. Cowling, Isaac Chun-Hai Fung

June 15, 2022

First we clear the workspace to get rid of leftover variables.

rm(list=ls())

Next we clear all graphic windows.

graphics.off();

We load packages that are required for the R simulation.

We set a seed so that the same simulation outputs can be obtained when simulations are repeated.

set.seed(1234)

# **SEAPIRD-V model**

- S refers to susceptible individuals.
- E refers to exposed individuals who are in the latent state.
- A refers to asymptomatic individuals: A percentage of the infected population makes transitions into the asymptomatic state. They are infectious.
- P refers to pre-symptomatic individuals: A percentage of the infected population makes transitions into the pre-symptomatic state. They are infectious.
- I refers to symptomatic individuals. They are infectious.
- R refers to recovered: Asymptomatic and Symptomatic individuals enter the recovery state.
- D refers to symptomatic individuals who died from COVID-19.
- V refers to individuals who become immune from COVID-19 infection after receiving two doses of the AstraZeneca vaccine.

### **Parameter definitions**

Parameters:

- c: transition rate from presymptomatic to symptomatic= 1/(incubation period latency period)
- beta: transmission coefficient
- q: recovery rate for asymptomatic individuals
- delta: probability that exposed persons become presymptomatically infected
- f: the inverse of the duration of individuals being symptomatic (equals to the recovery rate for symptomatic individuals)
- u: relative transmissibility of asymptomatic individuals
- r: relative transmissibility of pre-symptomatic individuals
- sigma: vaccine efficacy
- v: vaccination rate
- chi: waning immunity of vaccinated individuals
- Ro: reproduction number
- z: age-specific case fatality ratio

In this study, two strains of COVID-19 were assessed by varying the reproduction numbers and vaccine efficacy with the values below

```
#values for R and vaccine efficacy for each strain
#initial
#Ro = 3.13
#sigma = 0.745
#delta variant
#Ro = 5.35
#sigma = 0.67
```

An age-specific case fatality ratio was calculated: We assumed 9% of deaths in the population occurred in children, 51% between 25 and 64 years, and 40% of deaths in the elderly. These translated into the following CFR: <25 yr = 0.002; 25-64 yr = 0.005; 65+ yr = 0.048. See Technical Appendix A for more details.

z= c(0.002, 0.005, 0.048)

We created a function for the age-stratified model with 9 compartments with the set of ordinary differential equations that defines the model.

```
agestratified <- function(time, state, parameters){</pre>
  ncompartment = 9 #number of compartments in the model
  nage = length (state)/ncompartment
       = as.matrix(state[1:nage])
  S
       = as.matrix(state[(nage+1):(2*nage)])
  Е
       = as.matrix(state[(2*nage+1):(3*nage)])
  А
       = as.matrix(state[(3*nage+1):(4*nage)])
  Ρ
  Ι
       = as.matrix(state[(4*nage+1):(5*nage)])
  R
       = as.matrix(state[(5*nage+1):(6*nage)])
       = as.matrix(state[(6*nage+1):(7*nage)])
  D
       = as.matrix(state[(7*nage+1):(8*nage)])
  V
```

```
L = as.matrix(state[(8*nage+1):(9*nage)])
  I[I<0] = 0
  with(as.list(parameters),{
          = S+E+P+I+A+R+D+V
    lambda = (I+u*A+r*P)/N
    dS = -beta*as.matrix(S)*(as.matrix(C)%*%(as.matrix(lambda)))+
      w*as.matrix(R)- v*sigma*as.matrix(S) + chi*as.matrix(V)
    dE = beta*as.matrix(S)*(as.matrix(C)%*%as.matrix(lambda))- k*as.matrix(E)
    dA = (1-delta)*k*as.matrix(E)-g*as.matrix(A)
    dP = delta*k*as.matrix(E)-c*as.matrix(P)
    dI = c*as.matrix(P)-f*as.matrix(I)
    dR = (1-z)*f*as.matrix(I)+q*as.matrix(A)-w*as.matrix(R)
    dD = z*f*as.matrix(I)
    dV = v*sigma*as.matrix(S)-chi*as.matrix(V)
    dL = k*as.matrix(E)
    out=c(dS, dE, dA, dP, dI, dR, dD, dV, dL)
    list (out)
  }
  )
}
```

We determined the number of persons in each age group assuming a population size of 30800000.

```
lcalculate_transmission_probability = 1
popul= 30800000
g= c(0.5608, 0.3948, 0.0444) #3 age classes explained above
N= popul*g #number in each age class
nage = length (g)
```

### Setting initial state for compartments

We assumed a % of each subpopulation was already infected, hence they were in the recovered compartment at the beginning of the simulation.

Two contact matrices were used in the study a) the first matrix is defined as the "main matrix".

C = matrix(0, nrow=nage, ncol=nage) C[1,1] = 23.58 C[1,2] = 9.31 C[1,3] = 0.87 C[2,1] = 13.01 C[2,2] = 15.05 C[2,3] = 1.53 C[3,1] = 2.29 C[3,2] = 2.44 C[3,3] = 0.54

```
#C = matrix(0, nrow=nage, ncol=nage)
#C[1,1] = 8.2
#C[1,2] = 5
#C[1,3] = 1
#C[2,1] = 2
#C[2,2] = 7.8
#C[2,3] = 2.8
#C[3,1] = 0.1
#C[3,2] = 2.2
#C[3,3] = 1.60
```

We set the parameter values used for calculating beta.

We defined the formulae for calculating the beta using the R0 from the largest eigenvalue.

```
if (lcalculate_transmission_probability==1){
    M = C
    M[1,1] = C[1,1]*g[1]/g[1]
    M[1,2] = C[1,2]*g[1]/g[2]
    M[1,3] = C[1,3]*g[1]/g[3]
    M[2,1] = C[2,1]*g[2]/g[1]
    M[2,2] = C[2,2]*g[2]/g[2]
    M[2,3] = C[2,3]*g[2]/g[3]
    M[3,1] = C[3,1]*g[3]/g[1]
    M[3,2] = C[3,2]*g[3]/g[2]
    M[3,3] = C[3,3]*g[3]/g[3]
    eig = eigen(M)
    # Re() function extracts the real part of a complex number, in the event
```

```
that the eigenvalue is a complex number.
Beta = ((Ro*c*f*q)/((delta*r*f*q)+(delta*c*q)+((1-
delta)*u*c*f)))/max(Re(eig$values))
beta=Beta
}else{
beta = 0.34
}
```

We defined the initial state conditions.

We created a vector for the parameters for initializing our model.

```
parameters = c(delta = 0.3),
               k
                     = 0.54,
                     = 0.344,
               С
               beta = Beta,
               q = 0.14,
                     = 0.0003519,
               V
               f
                     = 0.064,
               u
                     = 0.75,
                     = 0.75,
               r
                     = 0.0055,
               W
               chi
                     = 0.0027,
               sigma = 0.745,
               Z
                     = z)
```

The model was simulated for 500 days to allow enough time for the second wave to emerge.

time = seq (0, 500, 1)

We solved the differential equations using the lsoda() function in the deSolve package:

We converted the data into a long format using the melt() function in the reshape2 package:

#### Scenario analysis of the impact of vaccine optimization strategies

Part 1: use v rates accounting for vaccine supplies only one million people can get vaccinated in 3 months

```
\#v = c(0,
                 0,
                            0.0082)
                                       #only elderly vaccinated
                 0.0009,
                            0)
                                       #adults vaccinated
\#v = c(\theta,
                                       #younger population vaccinated
\#v = c(0.0006.
                 0,
                            0)
                                       #adults and younger vaccinated
\#v = c(0.0004,
                 0.0004,
                            0)
\#v = c(0,
                            0)
                                       #no vaccination
                 0,
#v= c(0.000361, 0.000361, 0.000361) #same vaccination rate
```

Part 2: only one million people can get vaccinated in 6 months

```
\#v = c(0,
                0,
                          0.0041)
                                   #only elderly vaccinated
\#v = c(\theta,
                                   #adults vaccinated
                0.00046,
                         0)
\#v = c(0.00032, 0,
                                   #younger population vaccinated
                          0)
\#v = c(0.00019, 0.00019, 0)
                                   #adults and younger vaccinated
\#v = c(0,
                0,
                                   #no vaccination
                          0)
#v= c(0.00018, 0.00018, 0.00018) #same vaccination rate
```

Part 3: only 500,000 get vaccinated in 3 months

```
\#v = c(0,
                         0.0041) #only elderly vaccinated
               0,
               0.00046, 0)
                                  #adults vaccinated
\#v = c(0,
\#v = c(0.00032, 0,
                                  #younger population vaccinated
                         0)
\#v = c(0.00019, 0.00019, 0)
                                  #adults and younger vaccinated
#v = c(0,
                         0)
                                  #no vaccination
               0,
#v= c(0.00018, 0.00018, 0.00018) #same vaccination rate
```

Part 4: only 500,000 get vaccinated in 6 months

```
\#v = c(0,
                        0.0021)
                                  #only elderly vaccinated
               0,
               0.00023, 0)
                                  #adults vaccinated
\#v = c(0,
\#v = c(0.00016, 0,
                                  #younger population vaccinated
                         0)
\#v = c(0.00009, 0.00009, 0)
                                  #adults and younger vaccinated
               0,
#v = c(0,
                         0)
                                  #no vaccination
#v= c(0.00009, 0.00009, 0.00009) #same vaccination rate
```

Part 5: only 2,000,000 get vaccinated in 3 months

```
\#v = c(0,
                              0.016)
                                          #only elderly vaccinated
                  0,
\#v = c(0,
                  0.0018.
                              0)
                                          #adults vaccinated
\#v = c(0.0013,
                              0)
                                          #younger population vaccinated
                  0,
\#v = c(0.00075,
                  0.00075.
                              0)
                                          #adults and younger vaccinated
\#v = c(0,
                  0,
                              0)
                                          #no vaccination
#v= c(0.0007215, 0.0007215, 0.0007215) #same vaccination rate
```

Part 6: only 2,000,000 get vaccinated in 6 months

```
0.0082)
                                     #only elderly vaccinated
\#v = c(0,
                0,
                0.00091,
                                     #adults vaccinated
\#v = c(0,
                          0)
#v= c(0.00064, 0,
                          0)
                                     #younger population vaccinated
\#v = c(0.00038, 0.00038,
                          0)
                                    #adults and younger vaccinated
                0,
\#v = c(0,
                          0)
                                     #no vaccination
#v= c(0.000361, 0.000361, 0.000361) #same vaccination rate
```

We defined parameter values for the simulation.

```
parameters = c(delta = 0.3),
               k
                     = 0.54,
               С
                     = 0.344.
               beta = Beta,
               q
                     = 0.14,
               V
                     = V,
               f
                     = 0.064,
                     = 0.75,
               u
               r
                     = 0.75,
                     = 0.0055,
               W
               chi = 0.0027,
               sigma = sigma,
               z = z)
```

We solved the differential equations as:

Calculating the percentage of population with each outcome under the various vaccination scenarios

The percentage of the population who are symptomatic at the peak:

```
cat("The % of the population who are symptomatic at the peak is
",(max(teta$I1+teta$I2+teta$I3)/popul)*100,"\n")
```

The % of population ever infected:

cat("The % of the population ever infected is ",(max(teta\$L1+teta\$L2+teta\$L3)/popul)\*100,"\n")

The % of population who died:

```
cat("The % of the population who died is
",(max(teta$D1+teta$D2+teta$D3)/popul)*100,"\n")
```